Abstract: This application provides a digital person training method and system, and a digital person driving system. According to the method, human-body pose estimation data in training data is extracted, and the human-body pose estimation data is input into an optimized pose estimation network to obtain human-body pose optimization data. Generation losses of position optimization data and acceleration optimization data in the human-body pose optimization data are calculated based on a loss function of the optimized pose estimation network, so as to minimize errors between position estimation data and acceleration estimation data and a real value. In this way, the optimized pose estimation network is driven to update a network parameter to obtain an optimal driving model that is based on the optimized pose estimation network. The errors between the position estimation data and the acceleration estimation data and the real value are minimized.

Abstract: This application provides a digital person training method and system, and a digital person driving system. According to the method, human-body pose estimation data in training data is extracted, and the human-body pose estimation data is input into an optimized pose estimation network to obtain human-body pose optimization data. Generation losses of position optimization data and acceleration optimization data in the human-body pose optimization data are calculated based on a loss function of the optimized pose estimation network, so as to minimize errors between position estimation data and acceleration estimation data and a real value. In this way, the optimized pose estimation network is driven to update a network parameter to obtain an optimal driving model that is based on the optimized pose estimation network. The errors between the position estimation data and the acceleration estimation data and the real value are minimized.

Abstract: Disclosed are a SARS-COV-2 antigen polypeptide, a recombinant adeno-associated virus (rAAV) expressing the polypeptide, and a vaccine containing the virus. A sequence of the antigen polypeptide is shown in SEQ ID NO: 1 and SEQ ID NO: 2. A method for preparing the recombinant adeno-associated virus comprises co-incubating pHelper, pRep2Cap5, and an expression vector, transfecting a cell in the presence of polyethyleneimine as a transfection reagent; culturing the cell, then collecting the cell by centrifugation, performing lysis and purification to obtain a purified liquid comprising the recombinant adeno-associated virus. The rAAV is delivered and expressed in vivo to produce a fusion antigen polypeptide, induces the production of serum neutralizing antibodies, which have a neutralizing titer to the novel SARS-COV-2 coronavirus and are expressed continuously; the rAAV composition can be used to immunize humans against the novel coronavirus pneumonia COVID-19.

Abstract: The present application provides a helper plasmid for preparing a recombinant adeno-associated virus (rAAV), including: 1) a coding sequence of an AAV Rep protein and a coding sequence of an AAV Cap protein; 2) at least one promoter sequence; and 3) at least one DA?sequence or AD? sequence, wherein the AD? sequence is a reverse complementary sequence of the DA? sequence. The present application also provides a method for increasing a production capacity of a rAAV using the helper plasmid. With an AD? sequence or a DA? sequence, the helper plasmid provided in the present application can significantly increase an AAV yield of a cell.

Abstract: Disclosed are a SARS-COV-2 antigen polypeptide, a recombinant adeno-associated virus (rAAV) expressing the polypeptide, and a vaccine containing the virus. A sequence of the antigen polypeptide is shown in SEQ NO. 1. and SEQ ID NO. 2. A method for preparing the recombinant adeno-associated virus comprises co-incubating pHelper, pRep2Cap5, and an expression vector, transfecting a cell in the presence of polyethyleneimine as a transfection reagent; culturing the cell, then collecting the cell by centrifugation, performing lysis and purification to obtain a purified liquid comprising the recombinant adeno-associated virus. The rAAV is delivered and expressed in vivo to produce a fusion antigen polypeptide, induces the production of serum neutralizing antibodies, which have a neutralizing titer to the novel SARS-COV-2 coronavirus and are expressed continuously; the rAAV composition can be used to immunize humans against the novel coronavirus pneumonia COVID-19.